Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glufosfamide in Recurrent Sensitive Small Cell Lung Carcinoma
NCT00435578Phase 2Terminated
- Sponsor
- Threshold Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glufosfamide in Small Cell Lung Cancer (SCLC), sponsored by Threshold Pharmaceuticals. Primary endpoints: Objective Response Rate and Safety and Tolerability. Started Feb 2007; status: terminated.
02
Drugs
glufosfamide
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT00435578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00435578.